You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 134 No. 3, March 1999 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (18)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Surgery
 •Surgical Interventions
 •Burns
 •Pediatric Surgery
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Growth Hormone Attenuates Tumor Necrosis Factor {alpha} in Burned Children

Minas T. Chrysopoulo, MD; Marc G. Jeschke, MD; Roque J. Ramirez, MD; Robert E. Barrow, PhD; David N. Herndon, MD

Arch Surg. 1999;134:283-286.

Background  Recombinant human growth hormone (rhGH) has been shown to favorably modulate the acute-phase response and may improve the clinical outcome.

Objective  To examine whether rhGH attenuates the elevated tumor necrosis factor {alpha} (TNF-{alpha}) levels that correlate with increased multiorgan failure and mortality in burned adults and children.

Design  Twenty children with burns of greater than 40% of the total body surface area were randomly divided into 2 groups to receive placebo (n=10) or rhGH, 0.2 mg/kg per day intramuscularly (n=10).

Setting  Pediatric burn hospital.

Main Outcome Measure  Serum TNF-{alpha} levels by enzyme-linked immunoassay at baseline (day 0) and at 21 and 42 days after injury. For statistical analysis, we used the Kruskal-Wallis and Friedman tests.

Results  No significant differences in age (mean ± SD, 6.2 ± 1.6 vs 5.0 ± 1.2 years) or percentage of total body surface area burn (mean ± SD, 65.1% ± 8.2% vs 57.1% ± 5.2%) could be shown between the groups given rhGH and placebo. Baseline TNF-{alpha} levels were elevated from reference values in both groups. Twenty-one and 42 days after rhGH administration, serum TNF-{alpha} levels were significantly decreased from those at baseline (P<.05). No significant decrease in TNF-{alpha} levels was observed in the placebo group (P=.5).

Conclusions  Recombinant human growth hormone significantly lowers serum TNF-{alpha} levels after burn injury. This is consistent with the beneficial effect that rhGH has on the acute-phase response.


From the Shriners Hospitals for Children, Galveston Burns Institute and the Department of Surgery, University of Texas Medical Branch, Galveston.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Growth hormone prevents acute liver injury induced by cardiopulmonary bypass in a rat model
An and Xiao
J. Thorac. Cardiovasc. Surg. 2007;134:342-350.
ABSTRACT | FULL TEXT  

The preventative role of growth hormone on acute liver injury induced by cardiopulmonary bypass in a rat model
An and Xiao
Eur. J. Cardiothorac. Surg. 2007;31:1037-1043.
ABSTRACT | FULL TEXT  

Endocrine Changes in Critical Illness
Nylen and Muller
J Intensive Care Med 2004;19:67-82.
ABSTRACT  

Modulation of Inflammatory and Catabolic Responses in Severely Burned Children by Early Burn Wound Excision in the First 24 Hours
Barret and Herndon
Arch Surg 2003;138:127-132.
ABSTRACT | FULL TEXT  

Fitness, Training, and the Growth Hormone{->}Insulin-Like Growth Factor I Axis in Prepubertal Girls
Eliakim et al.
J. Clin. Endocrinol. Metab. 2001;86:2797-2802.
ABSTRACT | FULL TEXT  

Attenuation of the Acute-Phase Response in Thermally Injured Rats by Cholesterol-Containing Cationic Liposomes Used as a Delivery System for Gene Therapy
Jeschke et al.
Arch Surg 1999;134:1098-1102.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.